UBS raised the firm’s price target on Tenet Healthcare (THC) to $260 from $238 and keeps a Buy rating on the shares. The firm updated its model following the Q3 earnings report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $232 from $225 at Morgan Stanley
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA